Safety and efficacy of renal denervation utilizing standard bidirectional EP catheter: preliminary Vietnamese findings

Submitted: 24 September 2024
Accepted: 18 November 2024
Published: 28 November 2024
Abstract Views: 49
PDF: 44
Publisher's note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.

Authors

Renal denervation (RDN) is a safe and effective treatment for hypertensive patients. However, data on its use with standard electrophysiology catheters, particularly from low- and middle-income countries, are limited. This study aimed to evaluate the acute safety and short-term efficacy of RDN in hypertensive patients using standard EP catheters from Vietnam. A prospective study was conducted from May 2023 to May 2024 at the Viet Nam National Heart Institute, Vietnam. A total of 22 patients (mean age 52.87±19.86 years, 12 male) with resistant hypertension underwent RDN by utilizing a standard bidirectional steerable radiofrequency (RF) ablation catheter with a 7 Fr diameter (Abbott, Chicago, IL, USA). Low-power RF applications have been applied along the length of both renal arteries. Renal ultrasound, blood tests, and 24-hour ambulatory blood pressure (BP) were checked at baseline, at 1 month, and at 3 months following RF ablation. The success rate of the renal artery approach with a standard bidirectional EP catheter was 100% (22/22 patients). The mean reduction of 24-hour ambulatory BP, and ambulatory daytime BP were respectively -8.72/-6.04 mmHg and -8.00/-6.09 mmHg at 1 month and -15.59/-9.22 mmHg and -15.27/-10.18 mmHg at 3 months (p<0.05 for systolic and diastolic BP) with unchanged medication. No severe complications were reported during the procedure and follow-up. Our initial results indicate the safety and efficacy of RDN as shown by a significant reduction of mean 24-hour ambulatory BP in comparison to baseline during short-term follow-up.

Dimensions

Altmetric

PlumX Metrics

Downloads

Download data is not yet available.

PlumX Metrics

PlumX Metrics  provide insights into the ways people interact with individual pieces of research output (articles, conference proceedings, book chapters, and many more) in the online environment. Examples include, when research is mentioned in the news or is tweeted about. Collectively known as PlumX Metrics, these metrics are divided into five categories to help make sense of the huge amounts of data involved and to enable analysis by comparing like with like.

Citations

Buso G, Agabiti-Rosei C, Lemoli M, et al. The global burden of resistant hypertension and potential treatment options. Eur Cardiol Rev 2024;19:e07. DOI: https://doi.org/10.15420/ecr.2023.51
Kario K, Kai H, Rakugi H, et al. Consensus statement on renal denervation by the Joint Committee of Japanese Society of Hypertension (JSH), Japanese Association of Cardiovascular Intervention and Therapeutics (CVIT), and the Japanese Circulation Society (JCS). Hypertens Res 2024;47:2624-32. DOI: https://doi.org/10.1038/s41440-024-01700-z
Cluett JL, Blazek O, Brown AL, et al. Renal denervation for the treatment of hypertension: a scientific statement from the American Heart Association. Hypertension 2024;81:e135-48. DOI: https://doi.org/10.1161/HYP.0000000000000240
Mancia G, Kreutz R, Brunström M, et al. 2023 ESH guidelines for the management of arterial hypertension The Task Force for the management of arterial hypertension of the European Society of Hypertension: endorsed by the International Society of Hypertension (ISH) and the European Renal Association (ERA). J Hypertens 2023;41:1874-2071. DOI: https://doi.org/10.1097/HJH.0000000000003480
Prochnau D, Otto S, Figulla HR, Surber R. Renal denervation with standard radiofrequency ablation catheter is effective in 24-hour ambulatory blood pressure reduction – follow-up at 1/3/6/12 months. Neth Heart J 2016;24:449-55. DOI: https://doi.org/10.1007/s12471-016-0839-1
Bharadwaj HR, Tan JK, Ali SH, et al. Examining the provision of renal denervation therapy in low- and middle-income nations: current landscape, challenges, future prospects - a mini perspective review. Curr Probl Cardiol 2024;49:102357. DOI: https://doi.org/10.1016/j.cpcardiol.2023.102357
Prochnau D, Lucas N, Kuehnert H, et al. Catheter-based renal denervation for drug-resistant hypertension by using a standard electrophysiology catheter. EuroIntervention 2012;7:1077-80. DOI: https://doi.org/10.4244/EIJV7I9A171
Azizi M, Daemen J, Lobo MD, et al. 12-month results from the unblinded phase of the RADIANCE-HTN SOLO trial of ultrasound renal denervation. JACC Cardiovasc Interv 2020;13:2922-33. DOI: https://doi.org/10.1016/j.jcin.2020.09.054
Ahmed M, Nudy M, Bussa R, et al. A systematic review, meta-analysis, and meta regression of the sham controlled renal denervation randomized controlled trials. Trends Cardiovasc Med 2023;33:490-8. DOI: https://doi.org/10.1016/j.tcm.2022.05.009
Sharp ASP, Sanderson A, Hansell N, et al. Renal denervation for uncontrolled hypertension: a systematic review and meta-analysis examining multiple subgroups. J Hypertens 2024;42:1133-44. DOI: https://doi.org/10.1097/HJH.0000000000003727
Kario K. Catheter‐based renal denervation ready for the management of hypertension: evidence, challenges, and perspectives. J Am Heart Assoc 2024;13:e037099. DOI: https://doi.org/10.1161/JAHA.124.037099
Gosse P, Cremer A, Kirtane AJ, et al. Ambulatory blood pressure monitoring to predict response to renal denervation: a post hoc analysis of the RADIANCE-HTN SOLO study. Hypertension 2021;77:529-36. DOI: https://doi.org/10.1161/HYPERTENSIONAHA.120.16292
Salehin S, Karnkowska B, Hamza I, et al. Renal denervation in the management of resistant hypertension: a comprehensive review of literature. Curr Probl Cardiol 2024;49:102137. DOI: https://doi.org/10.1016/j.cpcardiol.2023.102137
Yalagudri S, Raju N, Das B, et al. Renal sympathetic denervation using an externally irrigated radiofrequency ablation catheter for treatment of resistant hypertension – acute safety and short term efficacy. Indian Heart J 2015;67:207-13. DOI: https://doi.org/10.1016/j.ihj.2015.02.020
Coates P, Tunev S, Trudel J, Hettrick DA. Time, temperature, power, and impedance considerations for radiofrequency catheter renal denervation. Cardiovasc Revasc Med 2022;42:171-7. DOI: https://doi.org/10.1016/j.carrev.2022.02.018
Bhatt DL, Vaduganathan M, Kandzari DE, et al. Long-term outcomes after catheter-based renal artery denervation for resistant hypertension: final follow-up of the randomised SYMPLICITY HTN-3 Trial. Lancet 2022;400:1405-16. DOI: https://doi.org/10.1016/S0140-6736(22)01787-1
Su E, Zhao L, Gao C, et al. Acute changes in morphology and renal vascular relaxation function after renal denervation using temperature-controlled radiofrequency catheter. BMC Cardiovasc Disord 2019;19:67. DOI: https://doi.org/10.1186/s12872-019-1053-z
Mahfoud F, Tunev S, Ewen S, et al. Impact of lesion placement on efficacy and safety of catheter-based radiofrequency renal denervation. J Am Coll Cardiol 2015;66:1766-75. DOI: https://doi.org/10.1016/j.jacc.2015.08.018

How to Cite

Hieu, T. B., Quang, N. N., & Hung, P. M. (2024). Safety and efficacy of renal denervation utilizing standard bidirectional EP catheter: preliminary Vietnamese findings. Italian Journal of Medicine, 18(4). https://doi.org/10.4081/itjm.2024.1816

Similar Articles

You may also start an advanced similarity search for this article.